Technology

Science Corporation Raises $400 Million Series D at $3.5 Billion Valuation

Martin HollowayPublished 6m ago3 min readBased on 1 source
Reading level
Science Corporation Raises $400 Million Series D at $3.5 Billion Valuation
Image by hysw001 from Pixabay

Science Corporation has raised a $400 million Series D round that values the brain-technology company at $3.5 billion, according to TechCrunch, which reported the funding on November 17, 2026.

The company was founded in 2021 by Max Hodak, a former president of Neuralink. The Series D backers include Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech. The backers range from venture firms to a healthcare provider and a research institute.

The first product is PRIMA, a chip that can be worn or implanted and that helps people with age-related macular degeneration recover some vision. Macular degeneration damages the central part of the retina, the light-sensitive layer at the back of the eye, which is the part used for reading and recognising faces. PRIMA is approved in Europe and available in Germany. The company is trialling the device in patients with Stargardt's disease, a separate inherited retinal disorder.

The US route is still ahead. Science Corporation aims to bring PRIMA to the United States through the FDA's Humanitarian Device Exemption, a regulatory route for devices that the company has not yet completed. Any American availability therefore depends on regulatory steps that have not yet happened, and the funding does not change that sequence.

The pipeline extends beyond the retina. The company is designing initial human trials of a bio-hybrid sensor that combines cultured neurons, or lab-grown nerve cells, with silicon. The work is led with Murat Günel, a neurosurgery professor at Yale. The sensor is at the design stage, and its trials are planned rather than underway.

The broader context here is the gap between the valuation and the current clinical footprint. The $3.5 billion figure rests on one approved product in one European market, a US application still in preparation, a trial in a second retinal indication, and a neural interface still being designed for human use. Investors are pricing the sequence of approvals and trial readouts, not revenue from an installed base.

In my view, the round is best read as a bet on execution across several programmes at once. The money gives the company room to run those programmes in parallel, and the next evidence will come from trial data and regulatory decisions rather than from financing announcements. Those are the milestones that will show whether the valuation holds.

Set against that timeline, the outcomes that matter most are clinical. If the PRIMA device helps patients with macular degeneration recover some vision across the wider populations and jurisdictions the company is pursuing, it would extend what implanted retinal interfaces can do. The bio-hybrid sensor, if it reaches human trials, would test a different approach to the same interface problem. Either result would matter to patients long before it matters to the cap table.